Press Releases

Date Title and Summary Additional Formats
Toggle Summary Arrowhead to Report Fiscal 2012 Fourth Quarter and Year-End Financial Results
Conference Call Scheduled for Thursday, December 20, 2012
View HTML
Toggle Summary Arrowhead Announces Pricing of a Public Offering of Common Stock and Warrants
Arrowhead Announces Pricing of a Public Offering of Common Stock and Warrants PASADENA, Calif. – December 7, 2012 – Arrowhead Research Corporation (NASDAQ: ARWR) today announced that it has priced a public offering of approximately 1.8 million units at a price to the public of $2.26 per unit.
View HTML
Toggle Summary Arrowhead Publishes First Ever Cholesterol-siRNA Mediated Gene Knockdown in Primates and Novel DPC Co-Injection Strategy
Arrowhead Publishes First Ever Cholesterol-siRNA Mediated Gene Knockdown in Primates and Novel DPC Co-Injection Strategy PASADENA, Calif. — November 27, 2012 — Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced the publication of data demonstrating that
View HTML
Toggle Summary Arrowhead Creates Hepatitis B Clinical Advisory Board and Names Dr. Robert Gish Chairman
Arrowhead Creates Hepatitis B Clinical Advisory Board and Names Dr. Robert Gish Chairman PASADENA, Calif. — November 13, 2012 — Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, announced today that prominent hepatologist Robert G.
View HTML
Toggle Summary Arrowhead Research to Present at BIO-Europe 2012
Arrowhead Research to Present at BIO-Europe 2012 PASADENA, Calif. — November 12, 2012 — Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced that Dr. Chris Anzalone, President and Chief Executive Officer, will present a corporate overview at the 18 th
View HTML
Toggle Summary Arrowhead Presents Data Showing 99% Target Knockdown in Monkeys Without Toxicity Using Subcutaneous Formulation of Dynamic Polyconjugate siRNA Delivery System
Arrowhead Presents Data Showing 99% Target Knockdown in Monkeys Without Toxicity Using Subcutaneous Formulation of Dynamic Polyconjugate siRNA Delivery System PASADENA, Calif. — October 29, 2012 — Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, announced that David
View HTML
Toggle Summary Arrowhead Research Receives Notice of Patent Allowance for New Formulation of DPC siRNA Delivery System Showing 500-Fold Increase in Potency
Arrowhead Research Receives Notice of Patent Allowance for New Formulation of DPC siRNA Delivery System Showing 500-Fold Increase in Potency PASADENA, Calif. — October 16, 2012 — Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced that it received a
View HTML
Toggle Summary Arrowhead to Present at Rodman and Renshaw Annual Global Investment Conference
Arrowhead to Present at Rodman and Renshaw Annual Global Investment Conference PASADENA, Calif. — September 5, 2012 — Arrowhead Research Corporation (NASDAQ: ARWR) , a targeted therapeutics company, today announced that its President and Chief Executive Officer, Dr.
View HTML
Toggle Summary Arrowhead Completes Enrollment in Phase 1b Trial of RNAi Drug Candidate CALAA-01
Arrowhead Completes Enrollment in Phase 1b Trial of RNAi Drug Candidate CALAA-01 PASADENA, Calif. — August 30, 2012 — Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced that, through its Calando Pharmaceuticals subsidiary, it has completed enrollment of
View HTML
Toggle Summary Arrowhead Reports Fiscal 2012 Third Quarter Financial Results
Arrowhead Reports Fiscal 2012 Third Quarter Financial Results PASADENA, Calif. — August 13, 2012 — Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced financial results for its fiscal 2012 third quarter ended June 30, 2012.
View HTML